Stocktoria

HALOZYME THERAPEUTICS, INC. HALO

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2003-01-30 · LEI

HALOZYME THERAPEUTICS, INC. statistics & valuation

Market cap$8.9B
P / E28.1×
P / S6.4×
P / FCF13.8×
Net margin22.7%
FCF margin46.2%
Net debt$2.0B
Net debt / EBITDA4.2×
Enterprise value USD$10.9B
EV / EBITDA22.7×
Earnings yield EBIT/EV4.3%
Return on capital20%
Graham number -95.3%$4.76

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($4.76); a green figure means the price is below it.

Profitability & efficiency

Net margin (%)
-70.20% 19.90% -52.90% -36.90% 48.20% 90.80% 30.60% 34.00% 43.70% 22.70% 2016201720182019202020212022202320242025
Gross margin (%)
2016201720182019202020212022202320242025
Operating margin (%)
-56.70% 25.60% -45.70% -34.50% 53.90% 62.20% 40.50% 40.70% 54.30% 33.60% 2016201720182019202020212022202320242025
Return on equity (%)
30.20% -32.30% -78.70% 85.50% 204.50% 119.00% 336.00% 122.10% 649.20% 2016201720182019202020212022202320242025
Shares outstanding
129.5M 142.8M 144.7M 144.3M 141.5M 146.8M 140.6M 134.2M 129.4M 123.9M 2016201720182019202020212022202320242025
Net debt ($)
$132.5M -$43.6M -$23.1M $262.9M -$147.7M $668.5M $1.27B $1.38B $1.39B $2.01B 2016201720182019202020212022202320242025
Share buybacks ($)
2016201720182019202020212022202320242025
Return on assets (%)
-39.40% 12.10% -18.20% -12.80% 22.30% 36.50% 11.00% 16.20% 21.50% 12.50% 2016201720182019202020212022202320242025
Free cash flow margin (%)
-36.50% 41.90% -35.70% -45.60% 19.80% 67.20% 35.60% 45.00% 46.10% 46.20% 2016201720182019202020212022202320242025
Debt / equity (×)
0.60× 0.14× 4.17× 0.00× 4.00× 8.87× 17.89× 4.14× 43.89× 2016201720182019202020212022202320242025
EPS ($)
-$0.81 $0.45 -$0.56 -$0.50 $0.91 $2.74 $1.44 $2.10 $3.43 $2.56 2016201720182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

P / E vs its own history

HALOZYME THERAPEUTICS, INC. trades at about 39.8× earnings — above its 10-year norm (10-year range 12.6×–52.3×, median 28×).

12.6× 52.3×

Shaded band = 10-year range (12.6×–52.3×); dot = today's 39.8×.

Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating margin33.6%54.3%40.7%40.5%62.2%53.9%-34.5%-45.7%25.6%-56.7%
Net margin22.7%43.7%34.0%30.6%90.8%48.2%-36.9%-52.9%19.9%-70.2%
FCF margin46.2%46.1%45.0%35.6%67.2%19.8%-45.6%-35.7%41.9%-36.5%
Return on assets12.5%21.5%16.2%11.0%36.5%22.3%-12.8%-18.2%12.1%-39.4%
Return on equity649.2%122.1%336.0%119.0%204.5%85.5%-78.7%-32.3%30.2%317.2%
Debt / equity43.89×4.14×17.89×8.87×4.00×0.00×4.17×0.14×0.60×-6.13×
Current ratio4.667.806.645.657.911.326.352.863.894.70

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.